费森尤斯医疗宣布其新的资本配置框架下的首次回购计划，规模至6亿欧元-动脉网

Fresenius Medical Care announces first tranche of its share buyback program of up to EUR 600 million as part of its new capital allocation framework

CISION 等信源发布 2025-08-11 19:00



可切换为仅中文







Total volume of the initial share buyback is up to

初始股份回购的总量高达

EUR 1 billion

10亿欧元

over two years

两年多

Share buyback to take place until

回购股票将持续到

August 10, 2027

2027年8月10日

BAD HOMBURG,

巴特洪堡，

Germany

德国

，

Aug. 11, 2025

2025年8月11日

/PRNewswire/ --

Fresenius Medical Care

费森尤斯医疗保健公司

(FME), the world's leading provider of products and services for individuals with renal diseases, announced the launch of the first tranche of its initial

（FME），全球领先的肾病患者产品和服务提供商，宣布了其首次发行的第一部分的推出。

EUR 1 billion

10亿欧元

share buyback, which is part of its new capital allocation framework as presented at its Capital Markets Day on

股票回购，这是其在资本市场日上公布的新资本配置框架的一部分。

June 17

6月17日

. Today, the first tranche of up to

。今天，第一期最高额度的

EUR 600 million

6亿欧元

was initiated, which is planned to be completed at the latest by

已启动，计划最迟于

April 30, 2026

2026年4月30日

。

'With the share buyback program, we are rapidly implementing an important component supporting our new FME Reignite strategy. The new program relates to initial share buybacks totaling

“通过股票回购计划，我们正在迅速实施支持我们新的FME Reignite战略的重要组成部分。新计划涉及初始股票回购总计

EUR one billion

10亿欧元

over two years. This underscores our goal of reigniting value creation for shareholders and enables our shareholders to participate in the strength of our company,' said

两年多。这强调了我们为股东重新创造价值的目标，并使我们的股东能够参与公司的实力，”

Helen Giza

海伦·吉扎

, CEO of Fresenius Medical Care.

，费森尤斯医疗保健公司首席执行官。

'The implementation of regular share buybacks in addition to a consistent dividend policy is part of our new capital allocation framework,' stated

“除了持续的股息政策外，实施定期股票回购也是我们新的资本配置框架的一部分，”

Martin Fischer

马丁·菲舍尔

, CFO of Fresenius Medical Care.

，费森尤斯医疗保健公司的首席财务官。

FME will provide regular updates on the progress of the share buyback program at

FME将定期提供股票回购计划的进展更新。

https://freseniusmedicalcare.com/en/investors/shares/share-buy-back/

https://freseniusmedicalcare.com/zh/investors/shares/share-buy-back/

。

About Fresenius Medical Care:

关于费森尤斯医疗：

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,676 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx.

费森尤斯医疗护理是全球领先的产品和服务供应商，为患有肾脏疾病的个人提供服务，其中大约有420万患者定期接受透析治疗。通过其拥有的3676家透析诊所网络，费森尤斯医疗护理为大约...提供透析治疗。

300,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS)..

全球30万名患者。费森尤斯医疗集团还是透析产品（如透析机或透析器）的领先供应商。费森尤斯医疗集团在法兰克福证券交易所（FME）和纽约证券交易所（FMS）上市。

For more information visit the company's website at

欲了解更多信息，请访问公司网站

www.freseniusmedicalcare.com

。

Disclaimer:

免责声明：

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing.

本发布包含受各种风险和不确定性影响的前瞻性陈述。由于多种因素，包括但不限于业务、经济和竞争状况的变化、法律变更、监管批准、临床研究结果、汇率波动、诉讼或调查程序中的不确定性以及融资的可用性，实际结果可能与这些前瞻性陈述中描述的结果有重大差异。

These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release..

这些以及其他风险和不确定性在费森尤斯医疗公司向美国证券交易委员会提交的报告中有详细说明。费森尤斯医疗公司不承担更新本新闻稿中前瞻性声明的任何责任。

Media contact

媒体联系人

Sven Jacobsen

斯文·雅各布森

T +49 171 28 79 127

电话：+49 171 28 79 127

sven.jacobsen@freseniusmedicalcare.com

斯文·雅各布森@费森尤斯医疗保健公司.com

Sabine Blessing

萨宾·布雷斯инг

T +49 171 74 81 259